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AbsTrACT
Artificial intelligence (AI) based on deep learning (DL) 
has sparked tremendous global interest in recent years. 
DL has been widely adopted in image recognition, 
speech recognition and natural language processing, 
but is only beginning to impact on healthcare. In 
ophthalmology, DL has been applied to fundus 
photographs, optical coherence tomography and visual 
fields, achieving robust classification performance in 
the detection of diabetic retinopathy and retinopathy of 
prematurity, the glaucoma-like disc, macular oedema and 
age-related macular degeneration. DL in ocular imaging 
may be used in conjunction with telemedicine as a 
possible solution to screen, diagnose and monitor major 
eye diseases for patients in primary care and community 
settings. Nonetheless, there are also potential challenges 
with DL application in ophthalmology, including clinical 
and technical challenges, explainability of the algorithm 
results, medicolegal issues, and physician and patient 
acceptance of the AI ’black-box’ algorithms. DL could 
potentially revolutionise how ophthalmology is practised 
in the future. This review provides a summary of the 
state-of-the-art DL systems described for ophthalmic 
applications, potential challenges in clinical deployment 
and the path forward.
InTroduCTIon
Artificial intelligence (AI) is the fourth industrial 
revolution in mankind’s history.1 Deep learning 
(DL) is a class of state-of-the-art machine learning 
techniques that has sparked tremendous global 
interest in the last few years.2 DL uses represen-
tation-learning methods with multiple levels of 
abstraction to process input data without the need 
for manual feature engineering, automatically 
recognising the intricate structures in high-di-
mensional data through projection onto a lower 
dimensional manifold.2 Compared with conven-
tional techniques, DL has been shown to achieve 
significantly higher accuracies in many domains, 
including natural language processing, computer 
vision3–5 and voice recognition.6
In medicine and healthcare, DL has been primarily 
applied to medical imaging analysis, in which DL 
systems have shown robust diagnostic perfor-
mance in detecting various medical conditions, 
including tuberculosis from chest X-rays,7 8 malig-
nant melanoma on skin photographs9 and lymph 
node metastases secondary to breast cancer from 
tissue sections.10 DL has similarly been applied to 
ocular imaging, principally fundus photographs 
and optical coherence tomography (OCT). Major 
ophthalmic diseases which DL techniques have been 
used for include diabetic retinopathy (DR),11–15 
glaucoma,11 16 age-related macular degeneration 
(AMD)11 17 18 and retinopathy of prematurity 
(ROP).19 DL has also been applied to estimate 
refractive error and cardiovascular risk factors (eg, 
age, blood pressure, smoking status and body mass 
index).20 21
A primary benefit of DL in ophthalmology could 
be in screening, such as for DR and ROP, for which 
well-established guidelines exist. Other conditions, 
such as glaucoma and AMD, may also require 
screening and long-term follow-up. However, 
screening requires tremendous manpower and 
financial resources from healthcare systems, in 
both developed countries and in low-income and 
middle-income countries. The use of DL, coupled 
with telemedicine, may be a long-term solution 
to screen and monitor patients within primary 
eye care settings. This review summarises new DL 
systems for ophthalmology applications, potential 
challenges in clinical deployment and potential 
paths forward.
dL AppLICATIons In ophThALmoLogy
diabetic retinopathy
Globally, 600 million people will have diabetes by 
2040, with a third having DR.22 A pooled analysis 
of 22 896 people with diabetes from 35 popula-
tion-based studies in the USA, Australia, Europe 
and Asia (between 1980 and 2008) showed that the 
overall prevalence of any DR (in type 1 and type 
2 diabetes) was 34.6%, with 7% vision-threatening 
diabetic retinopathy.22 Screening for DR, coupled 
with timely referral and treatment, is a universally 
accepted strategy for blindness prevention. DR 
screening can be performed by different health-
care professionals, including ophthalmologists, 
optometrists, general practitioners, screening tech-
nicians and clinical photographers. The screening 
methods comprise direct ophthalmoscopy,23 dilated 
slit lamp biomicroscopy with a hand-held lens (90 
D or 78 D),24 mydriatic or non-mydriatic retinal 
photography,23 teleretinal screening,25 and retinal 
video recording.26 Nonetheless, DR screening 
programmes are challenged by issues related to 
implementation, availability of human assessors and 
long-term financial sustainability.27
Over the past few years, DL has revolutionised 
the diagnostic performance in detecting DR.2 Using 
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Table 1 Summary table for the different DL systems in the detection of referable diabetic retinopathy, glaucoma suspect, age-related macular 
degeneration and retinopathy of prematurity using fundus photographs
dL systems year Test data sets Test images (n) Cnn AuC sensitivity (%) specificity (%)
Referable diabetic retinopathy 
  Abràmoff et al14 2016 Messidor-2 1748 AlexNet/VGG 0.98 96.80 87.00
  Gulshan et al12 2016 Messidor-2 1748 Inception-V3 0.99 87 98.50
96.10 93.90
EyePACS-1 9963 0.991 90.30 98.10
97.50 93.40
  Gargeya and Leng15 2017 Kaggle images 75 137 Customised CNN 0.97 NA NA
  E-Ophtha 463 0.96 NA NA
  Messidor-2 1748 0.94 NA NA
  Ting et al11 2017 SiDRP 14–15 71 896 VGG-19 0.936 90.50 91.60
  Guangdong 15 798 0.949 98.70 81.60
  SIMES 3052 0.889 97.10 82.00
  SINDI 4512 0.917 99.3 73.3
  SCES 1936 0.919 100 76.30
  BES 1052 0.929 94.40 88.50
  AFEDS 1968 0.98 98.80 86.50
  RVEEH 2302 0.983 98.90 92.20
  Mexican 1172 0.95 91.80 84.80
  CUHK 1254 0.948 99.3 83.10
  HKU 7706 0.964 100 81.30
  Abràmoff et al28 2018 10 primary care practice 
sites from the USA
892 patients Alex/VGG NA 87.2 90.7
Glaucoma suspect* 
  Ting et al11 2017 SiDRP 14–15 71 896 VGG-19 0.942 96.40 93.20
  Li et al16 2018 Guangdong 48 116 0.986 95.60 92.00
Age-related macular degeneration 
  Ting et al11 2017 SiDRP 14–15 35 948 VGG-19 0.932 93.20 88.70
  Burlina et al17 2017 AREDS 120 656 AlexNet, OverFeat 0.940–0.96 NA NA




Retinopathy of prematurity 
  Brown et al19 2018 i-ROP 100 Inception-V1 and U-Net NA 100 94
The diagnostic performance is not comparable between the different DL systems given the different data sets used in the individual study.
*Definition of glaucoma suspect: (1) Ting et al11—vertical cup to disc ratio of 0.8 or greater, and any glaucomatous disc changes; (2) Li et al16—vertical cup to disc ratio of 0.7 or 
greater, and any glaucomatous disc changes.
AFEDS, African American Eye Disease Study; AREDS, Age-Related Eye Disease Study; AUC, area under the receiver operating characteristic curve; BES, Beijing Eye Study; CNN, 
convolutional neural network; CUHK, Chinese University Hong Kong; DL, deep learning; SiDRP 14–15, Singapore Integrated Diabetic Retinopathy Screening Programme; HKU, 
Hong Kong University; NA, not available; RVEEH, Royal Victorian Eye and Ear Hospital; SCES, Singapore Chinese Eye Study; SIMES, Singapore Malay Eye Study; SINDI, Singapore 
Indian Eye Study.
this technique, many groups have shown excellent diagnostic 
performance (table 1).14 Abràmoff et al14 showed that a DL 
system was able to achieve an area under the receiver operating 
characteristic curve (AUC) of 0.980, with sensitivity and speci-
ficity of 96.8% and 87.0%, respectively, in the detection of refer-
able DR (defined as moderate non-proliferative DR or worse, 
including diabetic macular oedema (DMO)) on Messidor-2 data 
set. Similarly, Gargeya and Leng15 reported an AUC of 0.97 
using cross-validation on the same data set, and 0.94 and 0.95 in 
two independent test sets (Messidor-2 and E-Ophtha).
More recently, Gulshan and colleagues12 from Google AI 
Healthcare reported another DL system with excellent diag-
nostic performance. The DL system was developed using 128 
175 retinal images, graded between 3 and 7 times for DR 
and DMO by a panel of 54 US licensed ophthalmologists and 
ophthalmology residents between May and December 2015. The 
test set consisted of approximately 10 000 images retrieved from 
two publicly available databases (EyePACS-1 and Messidor-2), 
graded by at least seven US board-certified ophthalmologists 
with high intragrader consistency. The AUC was 0.991 and 
0.990 for EyePACS-1 and Messidor-2, respectively (table 1).
Although a number of groups have demonstrated good results 
using DL systems on publicly available data sets, the DL systems 
were not tested in real-world DR screening programmes. In 
addition, the generalisability of a DL system to populations of 
different ethnicities, and retinal images captured using different 
cameras, still remains uncertain. Ting et al11 reported a clinically 
acceptable diagnostic performance of a DL system, developed 
and tested using the Singapore Integrated Diabetic Retinop-
athy Programme over a 5-year period, and 10 external data 
sets recruited from 6 different countries, including Singapore, 
China, Hong Kong, Mexico, USA and Australia. The DL system, 
developed using the DL architecture VGG-19, was reported 
to have AUC, sensitivity and specificity of 0.936, 90.5% and 
91.6% in detecting referable DR. For vision-threatening DR, 
the corresponding statistics were 0.958, 100% and 91.1%. The 
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Table 2 Summary table for the different DL systems in the detection of retinal diseases using OCT
dL systems year disease oCT machines Test images Cnn AuC Accuracy (%) sensitivity (%) specificity (%)
Lee et al13 32 2017 Exudative AMD Spectralis 20 613 VGG-16 0.928 87.60 84.60 91.50
Trader et al33 2018 Exudative AMD Spectralis 100 Inception-V3 0.980 100 NA NA
Kermany et al34 2018 CNV Spectralis 1000 Inception-V3
DMO
Drusen
1. Multiclass comparison 0.999 96.50 97.80 97.40
2. Limited model 0.988 93.40 96.60 94.00
3. Binary model
CNV vs normal 1 100 100 100
DMO vs normal 0.999 98.20 96.80 99.60
Drusen vs normal 0.999 99 98 99.20
De Fauw et al43 2018 Urgent, semiurgent, 
routine and observation 
only






Normal, CNV, macular 
oedema, FTMH, PTMH, 
CSR, VMT, GA, drusen, 
ERM
Spectralis 116 patients 2. Deep classification 
network using a custom 29 






The diagnostic performance is not comparable between the different DL systems given the different data sets used in the individual study. AUC for specific conditions: CNV 
0.993; macular oedema 0.990; normal 0.995; FTMH 1.00; PTMH 0.999; CSR 0.995; VMT 0.980; GA 0.990; drusen 0.967; and ERM 0.966.
AMD, age-related macular degeneration; AUC, area under the receiver operating characteristic curve; CNN, convolutional neural network; CNV, choroidal neovascularisation; CSR, 
central serous chorioretinopathy; DL, deep learning; DMO, diabetic macular oedema; ERM, epiretinal membrane; FTMH, full-thickness macula hole; GA, geographic atrophy; NA, 
not available; OCT, optical coherence tomography; PTMH, partial thickness macula hole; VMT, vitreomacular traction.
AUC ranged from 0.889 to 0.983 for the 10 external data sets 
(n=40 752 images). More recently, the DL system, developed 
by Abramoff et al,28 has obtained a US Food and Drug Admin-
istration approval for the diagnosis of DR. It was evaluated in 
a prospective, although observational setting, achieving 87.2% 
sensitivity and 90.7% specificity.28
Age-related macular degeneration
AMD is a major cause of vision impairment in the elderly popu-
lation globally. The Age-Related Eye Disease Study (AREDS) 
classified AMD stages into none, early, intermediate and late 
AMD.29 The American Academy of Ophthalmology recom-
mends that people with intermediate AMD should be at least 
seen once every 2 years. It is projected that 288 million patients 
may have some forms of AMD by 2040,30 with approximately 
10% having intermediate AMD or worse.29 With the ageing 
population, there is an urgent clinical need to have a robust DL 
system to screen these patients for further evaluation in tertiary 
eye care centres.
Ting et al11 reported a clinically acceptable DL system diag-
nostic performance in detecting referable AMD (table 1). 
Specifically, the DL system was trained and tested using 108 
558 retinal images from 38 189 patients. Fovea-centred images 
without macula segmentation were used in this study. Given that 
this was the DR screening population, there were relatively few 
patients with referable AMD. For the other two studies,17 18 DL 
systems were developed using the AREDS data set, with a high 
number of referable AMD (intermediate AMD or worse). Using 
a fivefold cross-validation, Burlina et al17 reported a diagnostic 
accuracy of between 88.4% and 91.6%, with an AUC of between 
0.94 and 0.96. Unlike Ting et al,11 the authors presegmented the 
macula region prior to training and testing, with an 80/20 split 
between the training and testing in each fold. In terms of the DL 
architecture, both AlexNet and OverFeat have been used, with 
AlexNet yielding a better performance. Using the same AREDS 
data set, Grassmann et al18 reported a sensitivity of 84.2% in the 
detection of any AMD. In this study, the authors used six convo-
lutional neural networks—AlexNet, GoogleNet, VGG, Incep-
tion-V3, ResNet and Inception-ResNet-V2—to train different 
models. Data augmentation was also used to increase the diver-
sity of data set and to reduce the risk of overfitting. For the 
AREDS data set, all the photographs were captured as analogue 
photographs and then digitised later. Whether this affects the DL 
system’s performance remains uncertain. In addition, all three 
abovementioned studies did not have any results for external 
validation on the individual DL systems.
dm, choroidal neovascularisation and other macular diseases
OCT has had a transformative effect on the management of 
macular diseases, specifically neovascular AMD and DMO. 
OCT also provides a near-microscopic view of the retina in vivo 
with quick acquisition protocols revealing structural detail that 
cannot be seen using other ophthalmic examination techniques. 
Thus, the number of macular OCTs has grown from 4.3 million 
in 2012 to 6.4 million in 2016 in the US Medicare population 
alone, and will most likely continue to grow worldwide.31
From a DL perspective, macular OCTs possess a number 
of attractive qualities as a modality for DL. First is the explo-
sive growth in the number of macular OCTs that are routinely 
collected around the world. This large number of OCTs is 
required to train DL systems where having many training exam-
ples can aid in the convergence of many-layered networks with 
millions of parameters. Second, macular OCTs have dense 
three-dimensional structural information that is usually consis-
tently captured. Unlike real-world images or even colour fundus 
photographs, the field of view of the macula and the foveal 
fixation is usually consistent from one volume scan to another. 
This lowers the complexity of the computer vision task signifi-
cantly and allows networks to reach meaningful performance 
with smaller data sets. Third, OCTs provide structural detail 
that is not easily visible using conventional imaging techniques 
 o
n




ol: first published as 10.1136/bjophthalmol-2018-313173 on 25 October 2018. Downloaded from 
170 Ting DSW, et al. Br J Ophthalmol 2019;103:167–175. doi:10.1136/bjophthalmol-2018-313173
review
Figure 1 Archetype analysis with 16 visual field (VF) archetypes (ATs) that were derived from an unsupervised computer algorithm described by 
Elze et al.49
and provide an avenue for uncovering novel biomarkers of the 
disease.
One of the first applications of DL to macular OCTs was in 
automated classification of AMD. Approximately 100 000 OCT 
B-scans were used to train a DL classifier based on VGG-16 to 
achieve an AUC of 0.97 (table 2).32 Few studies used a technique 
known as transfer learning, where a neural network is pretrained 
on ImageNet and subsequently then trained on OCT B-scans for 
retinal disease classification.33–35 Of note, these initial studies 
involve the use of two-dimensional DL models trained on single 
OCT B-scans rather than three-dimensional models trained on 
OCT volumes. This may be a barrier to their potential clinical 
applicability.
DL has also had a transformative impact in boundary and 
feature-level segmentation using neural networks that have been 
developed for semantic segmentation such as the U-Net.36 Specif-
ically, these networks have been trained to segment intraretinal 
fluid cysts and subretinal fluid on OCT B-scans.13 37 38 Deep 
convolutional networks surpassed traditional methods in the 
quality of segmentation of retinal anatomical boundaries.39–41 
Also similar approaches were used to segment en-face OCTA 
images to segment the foveal avascular zone.42
More recently, DeepMind and the Moorfields Eye Hospital 
have combined the power of neural networks for both 
segmentation and classification tasks using a novel AI frame-
work. In this approach, a segmentation network is first used to 
delineate a range of 15 different retinal morphological features 
and OCT acquisition artefacts. The output of this network is 
then passed to a classification network which makes a referral 
triage decision from four categories (urgent, semiurgent, 
routine, observation) and classifies the presence of 10 different 
OCT pathologies (choroidal neovascularisation (CNV), macular 
oedema without CNV, drusen, geographic atrophy, epiretinal 
membrane, vitreomacular traction, full-thickness macular hole, 
partial thickness macular hole, central serous retinopathy and 
‘normal’).43 Using this approach, the Moorfields-DeepMind 
system reports a performance on par with experts for these clas-
sification tasks (although in a retrospective setting). Moreover, 
the generation of an intermediate tissue representation by the 
first, segmentation network means that the framework can be 
generalised across OCT systems from multiple different vendors 
without prohibitive requirements for retraining. In the near 
term, this DL system will be implemented in an existing real-
world clinical pathway—the rapid access ‘virtual’ clinics that are 
now widely used for triaging of macular disease in the UK.44 In 
the longer term, the system could be used in triaging patients 
outside the hospital setting, particularly as OCT systems are 
increasingly being adopted by optometrists in the community.45
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Table 3 The clinical and technical challenges in building and deploying deep learning (DL) techniques from ’bench to bedside’
steps potential challenges
1. Identification of training data 
sets
1. Patients’ consent and confidentiality issues.
2. Varying standards and regulations between the different institutional review boards.
3. Small training data sets for rare disease (eg, ocular tumours) or common diseases that are not captured in routine (eg, cataracts).
2. Validation and testing data 
sets
1. Lack of sample size—not sufficiently powered.
2. Lack of generalisability—not tested widely in different populations or on data collected from different devices.
3. Explainability of the results 1. Demonstration of the regions ‘deemed’ abnormal by DL.
2. Methods to generate heat maps—occlusion tests, class activation, integrated gradient method, soft attention map and so on.
4. Clinical deployment of DL 
Systems
1. Recommendation of the potential clinical deployment sites.
2. Application of regulatory approval from health authorities (eg, US Food and Drug Administration, Europe CE marking and so on).
3. Conducting prospective clinical trials.
4. Medical rebate scheme and medicolegal requirement.
5. Ethical challenges.
glaucoma
The global prevalence of glaucoma for people aged 40–80 is 
3.4%, and by the year 2040 it is projected there will be approx-
imately 112 million affected individuals worldwide.46 Clinicians 
and patients alike would welcome improvements in disease 
detection, assessment of progressive structural and functional 
damage, treatment optimisation so as to prevent visual disability, 
and accurate long-term prognosis.
Glaucoma is an optic nerve disease categorised by excavation 
and erosion of the neuroretinal rim that clinically manifests itself 
by increased optic nerve head (ONH) cupping. Yet, because 
the ONH area varies by fivefold, there is virtually no cup to 
disc ratio (CDR) that defines pathological cupping, hampering 
disease detection.47 Li et al16 and Ting et al11 trained computer 
algorithms to detect the glaucoma-like disc, defined as a vertical 
CDR of 0.7 and 0.8, respectively. Investigators have also applied 
machine learning methods to distinguish glaucomatous nerve 
fibre layer damage from normal scans on wide-angle OCTs 
(9×12 mm).48 Future opportunities include training a neural 
network to identify the disc that would be associated with mani-
fest visual field (VF) loss across the spectrum of disc size, as our 
current treatment strategies are aligned with slowing disease 
detection. Furthermore, DL could be used to detect progressive 
structural optic nerve changes in glaucoma.
In glaucoma, retinal ganglion cell axons atrophy in a confined 
space within the ONH and ophthalmologists typically rely on 
low dimensional psychophysical data to detect the functional 
consequences of that damage. The outputs from these tests 
typically provide reliability parameters, age-matched normative 
comparisons and summary global indices, but more detailed 
analysis of this functional data is lacking. Elze et al49 developed 
an unsupervised computer program to analyse VF that recog-
nises clinically relevant VF loss patterns and assigns a weighting 
coefficient for each of them (figure 1). This method has proven 
useful in the detection of early VF loss from glaucoma.50 
Furthermore, a myriad of computer programs to detect VF 
progression exist, ranging from assessment of global indices over 
time to point-wise analyses, to sectoral VF analysis; however, 
these approaches are often not aligned with clinical ground truth 
nor with one another.51 52 Yousefi et al53 developed a machine-
based algorithm that detected VF progression earlier than these 
conventional strategies. More machine learning algorithms that 
provide quantitative information about regional VF progression 
can be expected in the future.
Although intraocular pressure (IOP)-lowering has been 
shown to be therapeutically effective in delaying glaucoma 
progression, some demonstrated that disease progression is 
still inevitable,54–56 suggesting that we have not arrived at 
optimised treatment regimens for the various forms of glau-
coma. Kazemian et al57 developed a clinical forecasting tool 
that uses tonometric and VF data to project disease trajecto-
ries at different target IOPs. Further refinement of this tool that 
integrates other ophthalmic and non-ophthalmic data would be 
useful to establish target IOPs and the best strategies to achieve 
them on a case-by-case basis. Finally, it is documented that 
patients with newly diagnosed glaucoma harbour fears of going 
blind58; perhaps, the use of machine learning that incorporates 
genome-wide data, lifestyle behaviour and medical history into a 
forecasting algorithm will allow early prognostication regarding 
the future risk of requiring invasive surgery or losing functional 
vision from glaucoma.
As machine learning algorithms are revised, the practising 
ophthalmologist will have a host of tools available to diagnose 
glaucoma, detect disease progression and identify optimised 
treatment strategies using a precision medicine approaches. In 
an ideal future scenario, they may also have clinical forecasting 
tools that inform patients as to their overall prognosis and 
expected clinical course with or without treatment.
retinopathy of prematurity
ROP is a leading cause of childhood blindness worldwide, with 
an annual incidence of ROP-related blindness of 32 000 world-
wide.59 The regional epidemiology of the disease varies based 
on a number of factors, including the number of preterm births, 
neonatal mortality of preterm children and capacity to monitor 
exposure to oxygen. ROP screening either directly via ophthal-
moscopic examination or telemedical evaluation using digital 
fundus photography can identify the earliest signs of severe 
ROP, and with timely treatment can prevent most cases of blind-
ness from ROP.60 61 Due to the high number of preterm births, 
reductions in neonatal mortality, and limited capacity for oxygen 
monitoring and ROP screening, the highest burden of blinding 
ROP today is in low-income and middle-income countries.62
There are two main barriers to effective implementation of 
ROP screening: (1) the diagnosis of ROP is subjective, with 
significant interexaminer variability in the diagnosis leading to 
inconsistent application of evidence-based interventions63; and 
(2) there are too few trained examiners in many regions of the 
world.64 Telemedicine has emerged as a viable model to address 
the latter problem, at least in regions where the cost of a fundus 
camera is not prohibitive, by allowing a single physician to virtu-
ally examine infants over a large geographical area. However, 
telemedicine itself does not solve the subjectivity problem in 
ROP diagnosis. Indeed, the acute-phase ROP study found nearly 
25% of telemedicine examinations by trained graders required 
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Figure 2 Some examples of heat maps showing the abnormal areas in the retina. (A) Severe non-proliferative diabetic retinopathy (NPDR); (B) 
geographic atrophy in advanced age-related macular degeneration (AMD) on fundus photographs11; and (C) diabetic macular oedema on optical 
coherence tomography.
adjudication because the graders disagreed on one of three 
criteria for clinically significant ROP.65
There have been a number of early attempts to use DL for 
automated diagnosis of ROP,19 66 which could potentially address 
both implementation barriers for ROP screening. Most recently, 
Brown et al19 reported the results of a fully automated DL system 
that could diagnose plus disease, the most important feature of 
severe ROP, with an AUC of 0.98 compared with a consensus 
reference standard diagnosis combining image-based diagnosis 
and ophthalmoscopy (table 1). When directly compared with 
the eight international experts in ROP diagnosis, the i-ROP DL 
system agreed with the consensus diagnosis more frequently 
than six out of eight experts. Subsequent work found that the 
i-ROP DL system could also produce a severity score for ROP 
that demonstrated promise for objective monitoring of disease 
progression, regression and response to treatment.67 When 
compared with the same set of 100 images ranked in order of 
disease severity by experts, the algorithm had 100% sensitivity 
an 94% specificity in the detection of pre-plus or worse disease.
potential challenges
Despite the high level of accuracy of the AI-based models in many 
of the diseases in ophthalmology, there are still many clinical and 
technical challenges for clinical implementation and real-time 
deployment of these models in clinical practice (table 3). These 
challenges could arise in different stages in both the research and 
clinical settings. First, many of the studies have used training data 
sets from relatively homogeneous populations.12 14 15 AI training 
and testing using retinal images is often subject to numerous 
variabilities, including width of field, field of view, image magni-
fication, image quality and participant ethnicities. Diversifying 
the data set, in terms of ethnicities, and image-capture hardware 
could help to address this challenge.11
Another challenge in the development of AI models in ophthal-
mology has been the limited availability of large amounts of data 
for both the rare diseases (eg, ocular tumours) and for common 
diseases which are not imaged routinely in clinical practice such 
as cataracts. Furthermore, there are diseases such as glaucoma 
and ROP where there will be disagreement and interobserver 
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Figure 3 A representative screenshot from the output of the Moorfields-DeepMind deep learning system for optical coherence tomography 
segmentation and classification. In this case, the system correctly diagnoses a case of central serous retinopathy with secondary choroidal 
neovascularisation and recommends urgent referral to an ophthalmologist. Through the creation of an intermediate tissue representation (seen here 
as two-dimensional thickness maps for each morphological parameter), the system provides ’explainability’ for the ophthalmologist.
variability in the definition of the disease phenotype. The algo-
rithm learns from what they are presented with. The software 
is unlikely to produce accurate outcomes if the training set of 
images given to the AI tool is too small or not representative 
of real patient populations. More evidence on ways of getting 
high-quality ground-truth labels is required for different imaging 
tools. Krause et al68 reported that adjudication grades by retina 
specialists were a more rigorous reference standard, especially 
to detect artefacts and missed microaneurysms in DR, than a 
majority decision and improved the algorithm performance.
Second, many AI groups have reported robust diagnostic 
performance for their DL systems, although some papers did not 
show how the power calculation was performed for the indepen-
dent data sets. A power calculation should take the following into 
consideration: the prevalence of the disease, type 1 and 2 errors, 
CIs, desired precision and so on. It is important to first preset 
the desired operating threshold on the training set, followed by 
analysis of performance metrics such as sensitivity and specificity 
on the test set to assess calibration of the algorithm.
Third, large-scale adoption of AI in healthcare is still not on 
the horizon as clinicians and patients are still concerned about 
AI and DL being ‘black-boxes’. In healthcare, it is not only 
the quantitative algorithmic performance, but the underlying 
features through which the algorithm classifies disease which 
is important to improve physician acceptance. Generating heat 
maps highlighting the regions of influence on the image which 
contributed to the algorithm conclusion may be a first step 
(figure 2), although such maps are often challenging to interpret 
(what does it mean if a map highlights an area of vitreous on 
an OCT of a patient with drusen?).69 They may also struggle to 
deal with negations (what would it mean to highlight the most 
important part of an ophthalmic image that demonstrates that 
there is no disease present?).70 71 An alternative approach has 
been used for the DL system developed by the Moorfields Eye 
Hospital and DeepMind—in this system, the generation of an 
intermediate tissue representation by a segmentation network 
is used to highlight for the clinician (and quantify) the rele-
vant areas of retinal pathology (figure 3).43 It is also important 
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to highlight that ‘interpretability’ of DL systems may mean 
different things to a healthcare professional than to a machine 
learning expert. Although it seems likely that interpretable 
algorithms will be more readily accepted by ophthalmologists, 
future applied clinical research will be necessary to determine 
whether this is the case and whether it leads to tangible benefits 
for patients in terms of clinical effectiveness.
Lastly, the current AI screening systems for DR have been 
developed and validated using two-dimensional images and lack 
stereoscopic qualities, thus making identification of elevated 
lesions like retinal tractions challenging. Incorporating the infor-
mation from multimodal imaging in future AI algorithms may 
potentially address this challenge. In addition, the medicolegal 
aspects and the regulatory approvals vary in different countries 
and settings, and more work will be needed in these areas. An 
important challenge to the clinical adoption of AI-based tech-
nology is how the patients entrust clinical care to machines. 
Keel et al72 evaluated the patient acceptability of AI-based DR 
screening within endocrinology outpatient setting and reported 
that 96% of participants were satisfied or very satisfied with the 
automated screening model.72 However, in different populations 
and settings, the patient’s acceptability for AI-based screening 
may vary and may pose challenge in its implementation.
ConCLusIons
DL is the state-of-the-art AI machine learning technique that has 
revolutionised the AI field. For ophthalmology, DL has shown 
clinically acceptable diagnostic performance in detecting many 
retinal diseases, in particular DR and ROP. Future research is 
crucial in evaluating the clinical deployment and cost-effective-
ness of different DL systems in the clinical practice. To improve 
clinical acceptance of DL systems, it is important to unravel the 
‘black-box’ nature of DL using existing and future methodolo-
gies. Although there are challenges ahead, DL will likely impact 
on the practice of medicine and ophthalmology in the coming 
decades.
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